FR3126869A1 - Pharmaceutical composition comprising metabolites derived from the bacterium Bacillus subtilis Gozen GZN-08 isolated from Camellia sinensis and modulating the immune response. - Google Patents

Pharmaceutical composition comprising metabolites derived from the bacterium Bacillus subtilis Gozen GZN-08 isolated from Camellia sinensis and modulating the immune response. Download PDF

Info

Publication number
FR3126869A1
FR3126869A1 FR2109752A FR2109752A FR3126869A1 FR 3126869 A1 FR3126869 A1 FR 3126869A1 FR 2109752 A FR2109752 A FR 2109752A FR 2109752 A FR2109752 A FR 2109752A FR 3126869 A1 FR3126869 A1 FR 3126869A1
Authority
FR
France
Prior art keywords
pharmaceutical composition
composition according
bacillus subtilis
production
increasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR2109752A
Other languages
French (fr)
Inventor
Machiko IKEOKA
Mizuho Nasu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gozen K K Japan
Original Assignee
Gozen K K Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gozen K K Japan filed Critical Gozen K K Japan
Priority to FR2109752A priority Critical patent/FR3126869A1/en
Publication of FR3126869A1 publication Critical patent/FR3126869A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/742Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L’invention concerne une composition pharmaceutique comprenant une association de bioactifs comprenant de la théanine et des polysaccharides extraits de Camellia sinensis, et au moins 2 métabolites, typiquement produits par la bactérie Bacillus subtilis, de préférence Bacillus subtilis Gozen GZN-08 isolée de Camellia sinensis. L’invention concerne également la composition pharmaceutique pour son utilisation pour moduler le microbiote pulmonaire tout en modulant l’intensité de la réponse du système immunitaire en rétablissant un taux normal de globules blancs, et pour augmenter la production d’anticorps tout en réduisant la production de cytokines pro inflammatoires.The invention relates to a pharmaceutical composition comprising a combination of bioactives comprising theanine and polysaccharides extracted from Camellia sinensis, and at least 2 metabolites, typically produced by the bacterium Bacillus subtilis, preferably Bacillus subtilis Gozen GZN-08 isolated from Camellia sinensis . The invention also relates to the pharmaceutical composition for its use to modulate the pulmonary microbiota while modulating the intensity of the response of the immune system by restoring a normal level of white blood cells, and to increase the production of antibodies while reducing the production pro-inflammatory cytokines.

Description

Composition pharmaceutique comprenant des métabolites issus de la bactérie Bacillus subtilis Gozen GZN-08 isolée deCamelliasinensiset modulant la réponse immunitaire.Pharmaceutical composition comprising metabolites from the Bacillus subtilis Gozen GZN-08 bacterium isolated from Camelliasinensis and modulating the immune response.

La présente invention a pour objet une composition pharmaceutique comprenant une association de théanine et de polysaccharides extraits deCamellia sinensis, et d’au moins 2 métabolites produits par la bactérieBacillus subtilis Gozen GZN-08parmi le groupe : acide gallique, lobéline, biotine, catéchine, pyridoxine, acide syringique, butyrate, propionate, zinc, acide linoléique, saikosaponine, acacétine, saponarine, acide butyrique, caractérisée en ce que ladite composition module le microbiote pulmonaire et augmente l’intensité de la réponse du système immunitaire.The subject of the present invention is a pharmaceutical composition comprising a combination of theanine and polysaccharides extracted from Camellia sinensis , and at least 2 metabolites produced by the bacterium Bacillus subtilis Gozen GZN-08 from the group: gallic acid, lobeline, biotin, catechin, pyridoxine, syringic acid, butyrate, propionate, zinc, linoleic acid, saikosaponin, acacetin, saponarin, butyric acid, characterized in that said composition modulates the pulmonary microbiota and increases the intensity of the immune system response.

On sait que le microbiote est l'ensemble des microorganismes notamment bactéries, levures, champignons ou virus vivant dans un environnement spécifique appelé le microbiome chez un hôte. L’être humain possède plusieurs microbiotes : intestinal, pulmonaire, vaginal, au niveau de la peau ou encore de la zone nez/bouche/pharynx. Le microbiote d’un individu se constitue à partir du microbiote vaginal de la mère lors de la naissance, qui va dès la naissance coloniser la peau tandis ce que le microbiote issu du lait maternel va coloniser les intestins. L’exposition aux bactéries de l’environnement aux antibiotiques, à l’alimentation ou encore aux facteurs génétiques vont ensuite faire évoluer le microbiote durant les premières années. La présence du microbiote permet de limiter le risque de colonisation par une bactérie pathogène. Avant la découverte du microbiote, les bactéries étaient considérées majoritairement comme néfastes ou pathogènes mais aujourd’hui le rôle du microbiote est mieux connu. On sait qu’il est essentiel dans le bon fonctionnement de la digestion, du métabolisme, du système immunitaire et même du système neurologique. Cependant l’équilibre du microbiote est fragile. On appelle dysbiose un déséquilibre de ce microbiote. Ce déséquilibre peut être causé par un événement perturbateur comme un changement d’environnement, d’alimentation ou de traitement médical. Une dysbiose peut favoriser de nombreuses maladies comme l’obésité, le diabète, les allergies ou encore la dépression.We know that the microbiota is the set of microorganisms including bacteria, yeasts, fungi or viruses living in a specific environment called the microbiome in a host. Human beings have several microbiota: intestinal, pulmonary, vaginal, in the skin or even in the nose/mouth/pharynx area. An individual's microbiota is formed from the mother's vaginal microbiota at birth, which will colonize the skin from birth, while the microbiota from breast milk will colonize the intestines. Exposure to environmental bacteria, antibiotics, food or even genetic factors will then cause the microbiota to evolve during the first years. The presence of the microbiota makes it possible to limit the risk of colonization by a pathogenic bacterium. Before the discovery of the microbiota, bacteria were mainly considered harmful or pathogenic, but today the role of the microbiota is better known. It is known to be essential in the proper functioning of digestion, metabolism, the immune system and even the neurological system. However, the balance of the microbiota is fragile. An imbalance of this microbiota is called dysbiosis. This imbalance can be caused by a disruptive event such as a change in environment, diet, or medical treatment. Dysbiosis can promote many diseases such as obesity, diabetes, allergies or depression.

L’inventeur s’est intéressé plus particulièrement au microbiote pulmonaire. Il a longtemps été pensé que les poumons étaient stériles, cependant les récentes études ont démontré que les poumons abritent un large éventail d'espèces microbiennes différentes. Il a été observé que le microbiote des voies aériennes est altéré dans le cadre de nombreux troubles respiratoires. La modulation du microbiote pulmonaire est donc un outil intéressant pour maintenir les poumons en bonne santé.The inventor was particularly interested in the pulmonary microbiota. The lungs have long been thought to be sterile, however recent studies have shown that the lungs harbor a wide range of different microbial species. The airway microbiota has been observed to be altered in many respiratory disorders. Modulating the lung microbiota is therefore an interesting tool to keep the lungs healthy.

Le microbiote intestinal, avec celui de la peau, est le plus important microbiote du corps. Il peut fermenter les résidus alimentaires indigestes, favoriser l'absorption de certains nutriments, assurer l'hydrolyse de plusieurs substances, participer à la synthèse de multiples vitamines et réguler diverses voies métaboliques. La flore intestinale est également impliquée dans le fonctionnement du système immunitaire intestinal, essentiel à la fonction de barrière de la paroi intestinale. En effet des bactéries commeEscherichia colicombattent directement la colonisation du tube digestif par des bactéries pathogènes grâce à des phénomènes de compétition et par la production de substances bactéricides. La flore intestinale est aussi très importante dès le plus jeune âge puisqu’elle permet au système immunitaire intestinal d’apprendre à faire la distinction entre les bactéries bonnes pour les corps et les bactéries pathogènes.The intestinal microbiota, along with that of the skin, is the most important microbiota in the body. It can ferment indigestible food residues, promote the absorption of certain nutrients, ensure the hydrolysis of several substances, participate in the synthesis of multiple vitamins and regulate various metabolic pathways. The intestinal flora is also involved in the functioning of the intestinal immune system, which is essential for the barrier function of the intestinal wall. In fact, bacteria such as Escherichia coli directly combat the colonization of the digestive tract by pathogenic bacteria thanks to competition phenomena and the production of bactericidal substances. The intestinal flora is also very important from an early age since it allows the intestinal immune system to learn to distinguish between bacteria that are good for the body and pathogenic bacteria.

On sait que l'influence du microbiote sur la formation de la réponse immunitaire est un sujet de plus en plus étudié aujourd'hui. Ces études indiquent l’importance de l’influence du microbiote sur son hôte et démontrent le rôle clef de certaines bactéries du microbiote dans l’activation du système immunitaire, notamment au niveau de l’intestin. Une dysbiose peut donc conduire à un dysfonctionnement dans l’activation de ce système, à une réponse immunitaire insuffisante, ou encore à la colonisation de bactéries pathogènes inflammatoires dans l’intestin.We know that the influence of the microbiota on the formation of the immune response is a subject that is increasingly studied today. These studies indicate the importance of the influence of the microbiota on its host and demonstrate the key role of certain microbiota bacteria in the activation of the immune system, particularly in the intestine. Dysbiosis can therefore lead to a dysfunction in the activation of this system, to an insufficient immune response, or to the colonization of inflammatory pathogenic bacteria in the intestine.

Des traitements à base de polysaccharides issus deCamellia sinensis(WO2011069781A1) ont été proposés afin de stimuler la réponse immunitaire, mais cette solution a une action limitée dans le temps puisqu’elle ne permet pas de lutter contre un déséquilibre du microbiote intestinal ou pulmonaire et donc de prévenir une future réaction insuffisante du système immunitaire en cas de dysbiose. D’autres solutions à base de probiotiques ont été proposées comme par exemple une souche deLactobacillus reuteripour prévenir ou traiter une dysbiose du microbiote et ainsi prévenir différents types de maladie liées à cette dysbiose (WO2016066763A1) ou encore une souche deLactobacillus rhamnosuspour favoriser une réponse immunitaire anti-infectieuse et/ou anti-inflammatoire (EP2983685A1). Cependant ces solutions font appel à des souches vivantes qui ne sont donc pas stables dans le temps et qui peuvent alors induire une baisse d’efficacité dans le temps. De plus, les souches vivantes ont un effet limité, dû non seulement à leur faible stabilité dans le temps, mais aussi car elles dépendent de la composition bactérienne du sujet qui peut limiter l’implantation de nouvelles bactéries et par conséquent leur efficacité.Treatments based on polysaccharides from Camellia sinensis (WO2011069781A1) have been proposed in order to stimulate the immune response, but this solution has a limited action over time since it does not make it possible to fight against an imbalance of the intestinal or pulmonary microbiota and therefore to prevent a future insufficient reaction of the immune system in the event of dysbiosis. Other solutions based on probiotics have been proposed, such as for example a strain of Lactobacillus reuteri to prevent or treat dysbiosis of the microbiota and thus prevent different types of disease linked to this dysbiosis (WO2016066763A1) or even a strain of Lactobacillus rhamnosus to promote an anti-infective and/or anti-inflammatory immune response (EP2983685A1). However, these solutions use live strains which are therefore not stable over time and which can then induce a drop in efficiency over time. Moreover, live strains have a limited effect, due not only to their low stability over time, but also because they depend on the bacterial composition of the subject, which can limit the implantation of new bacteria and consequently their effectiveness.

C’est en étudiant l’effet de la fermentation sur l’efficacité des extraits de thé que la Demanderesse a découvert de manière tout à fait inattendue que ces problèmes peuvent être facilement résolus par l’utilisation d’une composition pharmaceutique comprenant une association de théanine et des polysaccharides extraits deCamellia sinensis, et d’au moins 2 métabolites, typiquement produits par une bactérie Bacillus subtilis, typiquementBacillus subtilis Gozen GZN-08, choisis dans le groupe : acide gallique, lobéline, biotine, catéchine, pyridoxine, acide syringique, butyrate, propionate, zinc, acide linoléique, saikosaponine, acacétine, saponarine, acide butyrique, caractérisée en ce que ladite composition module le microbiote pulmonaire et module l’intensité de la réponse du système immunitaire.It was by studying the effect of fermentation on the effectiveness of tea extracts that the Applicant discovered quite unexpectedly that these problems can be easily solved by the use of a pharmaceutical composition comprising a combination of theanine and polysaccharides extracted from Camellia sinensis , and from at least 2 metabolites, typically produced by a Bacillus subtilis bacterium, typically Bacillus subtilis Gozen GZN-08 , chosen from the group: gallic acid, lobeline, biotin, catechin, pyridoxine, acid syringic, butyrate, propionate, zinc, linoleic acid, saikosaponin, acacetin, saponarin, butyric acid, characterized in that said composition modulates the pulmonary microbiota and modulates the intensity of the response of the immune system.

RESUMÉSUMMARY

Dans un premier aspect l’invention concerne une composition pharmaceutique comprenant une association de bioactifs comprenant de la théanine et des polysaccharides extraits des feuilles de matchaCamellia sinensis, et au moins 2 métabolites produits par une bactérieBacillus subtilis, choisis dans le groupe : acide gallique, lobéline, biotine, catéchine, pyridoxine, acide syringique, butyrate, propionate, zinc, acide linoléique, saikosaponine, acacétine, saponarine. Typiquement, la composition pharmaceutique est destinée à moduler le microbiote pulmonaire et à moduler l’intensité de la réponse du système immunitaire.In a first aspect, the invention relates to a pharmaceutical composition comprising a combination of bioactives comprising theanine and polysaccharides extracted from Camellia sinensis matcha leaves, and at least 2 metabolites produced by a Bacillus subtilis bacterium, chosen from the group: gallic acid , lobeline, biotin, catechin, pyridoxine, syringic acid, butyrate, propionate, zinc, linoleic acid, saikosaponin, acacetin, saponarin. Typically, the pharmaceutical composition is intended to modulate the pulmonary microbiota and to modulate the intensity of the response of the immune system.

Dans un mode de réalisation la composition pharmaceutique comprend du zinc à une concentration d’au moins 0,5% et de préférence d’au moins 2% en poids par rapport au poids total de bioactifs dans ladite composition et des polysaccharides à une concentration d’au moins 0,5% et de préférence d’au moins 5%.In one embodiment, the pharmaceutical composition comprises zinc at a concentration of at least 0.5% and preferably at least 2% by weight relative to the total weight of bioactives in said composition and polysaccharides at a concentration of at least 0.5% and preferably at least 5%.

La composition pharmaceutique de l’invention peut être sous la forme de poudre ou d’émulsion lyophilisée. Elle peut être notamment sous forme de crèmes, liquides, pâtes, inhalateurs, lotions, émulsions, gels, sirops, solides, sirop, poudres, masques, stick, comprimés, sprays, aérosol, gélules, huiles, ou boisson prête à l’emploi.The pharmaceutical composition of the invention may be in the form of a powder or a freeze-dried emulsion. It may in particular be in the form of creams, liquids, pastes, inhalers, lotions, emulsions, gels, syrups, solids, syrup, powders, masks, sticks, tablets, sprays, aerosols, capsules, oils, or ready-to-use drinks. .

L’invention concerne également un procédé de préparation d’une composition pharmaceutique selon l’invention. Le procédé comprend au moins une étape de fermentation lente deCamelia sinensisen présence de la bactérieBacillus subtilis Gozen GZN-08.The invention also relates to a process for the preparation of a pharmaceutical composition according to the invention. The method comprises at least one step of slow fermentation of Camelia sinensis in the presence of the bacterium Bacillus subtilis Gozen GZN-08 .

L’invention concerne en outre la composition pharmaceutique telle que décrite ci-dessus, pour son utilisation dans :The invention further relates to the pharmaceutical composition as described above, for its use in:

- le traitement ou la prévention de la dysbiose, de préférence de la dysbiose pulmonaire et/ou intestinale.- the treatment or prevention of dysbiosis, preferably pulmonary and/or intestinal dysbiosis.

- la diminution des signes de l’inflammation et dans la diminution de production des cytokines pro inflammatoires; dans le rétablissement d’un taux normal de globules blancs et l’augmentation de la production d’anticorps par les lymphocytes ;- the decrease in the signs of inflammation and in the decrease in the production of pro-inflammatory cytokines; in the restoration of a normal level of white blood cells and the increase in the production of antibodies by the lymphocytes;

- le rétablissement d’un taux normal de globules blancs et l’augmentation de la production d’anticorps par les lymphocytes ;- the restoration of a normal level of white blood cells and the increase in the production of antibodies by the lymphocytes;

- l’augmentation de la production d’oxide nitrique par les cellules endothéliales et dans la modulation de la vasodilatation des vaisseaux sanguins ; et/ou- the increase in nitric oxide production by endothelial cells and in the modulation of the vasodilation of blood vessels; and or

- l’augmentation de la stabilité de l’hémoglobine et dans l‘augmentation du taux d’hémoglobine circulante.- the increase in the stability of hemoglobin and in the increase in the level of circulating hemoglobin.

Claims (9)

Composition pharmaceutique destinée à moduler le microbiote pulmonaire et à moduler l’intensité de la réponse du système immunitaire caractérisée en ce qu’elle comprend une association de bioactifs comprenant de la théanine et des polysaccharides extraits des feuilles de matchaCamellia sinensis, et au moins 2 métabolites produits par une bactérieBacillus subtilischoisis dans le groupe : acide gallique, lobéline, biotine, catéchine, pyridoxine, acide syringique, butyrate, propionate, zinc, acide linoléique, saikosaponine, acacétine, saponarine.Pharmaceutical composition intended to modulate the pulmonary microbiota and to modulate the intensity of the response of the immune system, characterized in that it comprises a combination of bioactive agents comprising theanine and polysaccharides extracted from Camellia sinensis matcha leaves, and at least 2 metabolites produced by Bacillus subtilis bacteria selected from the group: gallic acid, lobeline, biotin, catechin, pyridoxine, syringic acid, butyrate, propionate, zinc, linoleic acid, saikosaponin, acacetin, saponarin. Composition pharmaceutique selon la revendication 1, caractérisée en ce qu’elle comprend du zinc à une concentration d’au moins 0,5% et de préférence d’au moins 2% en poids par rapport au poids total de bioactifs dans ladite composition et des polysaccharides à une concentration d’au moins 0,5% et de préférence d’au moins 5%.Pharmaceutical composition according to Claim 1, characterized in that it comprises zinc at a concentration of at least 0.5% and preferably of at least 2% by weight relative to the total weight of bioactives in the said composition and polysaccharides at a concentration of at least 0.5% and preferably at least 5%. Composition pharmaceutique selon la revendication 1 ou la revendication 2, caractérisée en ce que la composition est sous la forme de poudre ou d’émulsion lyophilisée, et de préférence sous forme de crèmes, liquides, pâtes, inhalateurs, lotions, émulsions, gels, sirops, solides, sirop, poudres, masques, stick, comprimés, sprays, aérosol, gélules, huiles, ou boisson prête à l’emploi.Pharmaceutical composition according to claim 1 or claim 2, characterized in that the composition is in the form of powder or freeze-dried emulsion, and preferably in the form of creams, liquids, pastes, inhalers, lotions, emulsions, gels, syrups , solids, syrup, powders, masks, sticks, tablets, sprays, aerosols, capsules, oils, or ready-to-use drinks. Procédé de préparation d’une composition pharmaceutique selon l’une quelconque des revendications 1 à 3, caractérisé en ce qu’il comprend au moins une étape de fermentation lente deCamelia sinensisen présence de la bactérieBacillus subtilis Gozen GZN-08.Process for the preparation of a pharmaceutical composition according to any one of Claims 1 to 3, characterized in that it comprises at least one stage of slow fermentation of Camelia sinensis in the presence of the bacterium Bacillus subtilis Gozen GZN-08 . Composition pharmaceutique selon l’une quelconque des revendications 1 à 3, pour son utilisation dans le traitement ou la prévention de la dysbiose, de préférence de la dysbiose pulmonaire et/ou intestinale.Pharmaceutical composition according to any one of Claims 1 to 3, for its use in the treatment or prevention of dysbiosis, preferably pulmonary and/or intestinal dysbiosis. Composition pharmaceutique selon l’une quelconque des revendications 1 à 3, pour son utilisation dans la diminution des signes de l’inflammation et dans la diminution de production des cytokines pro inflammatoires ; dans le rétablissement d’un taux normal de globules blancs et l’augmentation de la production d’anticorps par les lymphocytes.Pharmaceutical composition according to any one of Claims 1 to 3, for its use in reducing the signs of inflammation and in reducing the production of pro-inflammatory cytokines; in restoring a normal level of white blood cells and increasing the production of antibodies by lymphocytes. Composition pharmaceutique selon l’une quelconque des revendications 1 à 3, pour son utilisation dans le rétablissement d’un taux normal de globules blancs et l’augmentation de la production d’anticorps par les lymphocytes.Pharmaceutical composition according to any one of Claims 1 to 3, for its use in restoring a normal level of white blood cells and increasing the production of antibodies by the lymphocytes. Composition pharmaceutique selon l’une quelconque des revendications 1 à 3, pour son utilisation dans l’augmentation de la production d’oxyde nitrique par les cellules endothéliales et dans la modulation de la vasodilatation des vaisseaux sanguins.Pharmaceutical composition according to any one of Claims 1 to 3, for its use in increasing the production of nitric oxide by endothelial cells and in modulating the vasodilation of blood vessels. Composition pharmaceutique selon l’une quelconque des revendications 1 à 3, pour son utilisation dans l’augmentation de la stabilité de l’hémoglobine et dans l‘augmentation du taux d’hémoglobine circulante.
Pharmaceutical composition according to any one of Claims 1 to 3, for its use in increasing the stability of hemoglobin and in increasing the rate of circulating hemoglobin.
FR2109752A 2021-09-16 2021-09-16 Pharmaceutical composition comprising metabolites derived from the bacterium Bacillus subtilis Gozen GZN-08 isolated from Camellia sinensis and modulating the immune response. Pending FR3126869A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR2109752A FR3126869A1 (en) 2021-09-16 2021-09-16 Pharmaceutical composition comprising metabolites derived from the bacterium Bacillus subtilis Gozen GZN-08 isolated from Camellia sinensis and modulating the immune response.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2109752 2021-09-16
FR2109752A FR3126869A1 (en) 2021-09-16 2021-09-16 Pharmaceutical composition comprising metabolites derived from the bacterium Bacillus subtilis Gozen GZN-08 isolated from Camellia sinensis and modulating the immune response.

Publications (1)

Publication Number Publication Date
FR3126869A1 true FR3126869A1 (en) 2023-03-17

Family

ID=78536373

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2109752A Pending FR3126869A1 (en) 2021-09-16 2021-09-16 Pharmaceutical composition comprising metabolites derived from the bacterium Bacillus subtilis Gozen GZN-08 isolated from Camellia sinensis and modulating the immune response.

Country Status (1)

Country Link
FR (1) FR3126869A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069781A1 (en) 2009-12-11 2011-06-16 Unilever Nv Polysaccharide suitable to modulate immune response
KR20140103488A (en) * 2013-02-18 2014-08-27 정읍시 Fermented green tea using microorganism and method for preparing the same
EP2983685A1 (en) 2013-04-09 2016-02-17 Pierre Fabre Medicament Composition comprising a combination of an elder extract and a strain of lactobacillus rhamnosus
WO2016066763A1 (en) 2014-10-29 2016-05-06 Nestec S.A. Use of l. reuteri for recovery of microbiota dysbiosis in early life
CN106132427A (en) * 2014-03-21 2016-11-16 株式会社爱茉莉太平洋 Compositions containing after fermentation tea extract
EP3878460A1 (en) * 2018-11-05 2021-09-15 Amorepacific Corporation Green tea extract having modified constituent content and composition comprising same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011069781A1 (en) 2009-12-11 2011-06-16 Unilever Nv Polysaccharide suitable to modulate immune response
KR20140103488A (en) * 2013-02-18 2014-08-27 정읍시 Fermented green tea using microorganism and method for preparing the same
EP2983685A1 (en) 2013-04-09 2016-02-17 Pierre Fabre Medicament Composition comprising a combination of an elder extract and a strain of lactobacillus rhamnosus
CN106132427A (en) * 2014-03-21 2016-11-16 株式会社爱茉莉太平洋 Compositions containing after fermentation tea extract
WO2016066763A1 (en) 2014-10-29 2016-05-06 Nestec S.A. Use of l. reuteri for recovery of microbiota dysbiosis in early life
EP3878460A1 (en) * 2018-11-05 2021-09-15 Amorepacific Corporation Green tea extract having modified constituent content and composition comprising same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHACKO SABU M ET AL: "Beneficial effects of green tea: A literature review", CHINESE MEDICINE, BIOMED CENTRAL LTD, LO, vol. 5, no. 1, 6 April 2010 (2010-04-06), pages 13, XP021081684, ISSN: 1749-8546, DOI: 10.1186/1749-8546-5-13 *
CHOWDHURY PRITOM ET AL: "Tea Bioactive Modulate Innate Immunity: In Perception to COVID-19 Pandemic", FRONTIERS IN IMMUNOLOGY, vol. 11, 28 October 2020 (2020-10-28), XP055905782, DOI: 10.3389/fimmu.2020.590716 *
HUYNH NGOC B.: "The Immunological Benefits of Green Tea (Camellia sinensis)", INTERNATIONAL JOURNAL OF BIOLOGY, vol. 9, no. 1, 20 December 2016 (2016-12-20), CA, pages 10, XP055905789, ISSN: 1916-9671, Retrieved from the Internet <URL:http://www.ccsenet.org/journal/index.php/ijb/article/viewFile/64249/35215> DOI: 10.5539/ijb.v9n1p10 *
LING-LING: "Tea Polysaccharides and Their Bioactivities", 30 October 2016 (2016-10-30), XP055905673, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274327/pdf/molecules-21-01449.pdf> [retrieved on 20220328] *

Similar Documents

Publication Publication Date Title
EP2124972B1 (en) Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems
US11304985B2 (en) Compositions and methods for promoting a healthy microbial flora in a mammal
JP4455333B2 (en) Probiotic bacteria: Lactobacillus fermentum
CA2709850C (en) Composition for human and/or animal nutrition, uses thereof and yeasts
US20210030818A1 (en) Compositions for use in balancing microbiome
EP2931289B1 (en) Chitin or derivatives thereof for the prevention and/or treatment of parasitoses
CN105054076B (en) A kind of alimentation composition and its application for helping to improve alzheimer&#39;s disease
HUE027565T2 (en) New method for obtaining a Lactobacillus reuteri strain useful in medical and veterinary prophylaxis and treatment
RU2671221C2 (en) Compositions comprising mixture of bacteria comprising pedoiococcus and lactobacillus and methods for decreasing effects of alcohol
JP2016521287A6 (en) Composition comprising a mixture of bacteria comprising Pediococcus and Lactobacillus, and method for reducing the effects of alcohol
US6368580B1 (en) Composition suitable as food integrator and for the treatment of intestinal disorders and alterations of the bacterial flora
FR3126869A1 (en) Pharmaceutical composition comprising metabolites derived from the bacterium Bacillus subtilis Gozen GZN-08 isolated from Camellia sinensis and modulating the immune response.
JP2007186529A (en) Method for decreasing emission of malodorous gas
CN109700832A (en) Pharmaceutical composition comprising bacillus licheniformis and American-cockroach-extract
RU2325166C1 (en) Pharmaceutical formulation of antibiotics and lactulose applied for prevention of enteral disbiosis caused by antibiotic therapy
CA2379727C (en) Use of propionic bacteria for producing propionic acid and/or propionates in the colon
CN109043224A (en) A kind of cleanser reducing cadmium enrichment in edible shellfish body
US20240335488A1 (en) Novel lactobacillus helveticus ua881 strain and probiotic composition for improving intestinal permeability and metabolic disorders
FR3122084A1 (en) Cosmetic or pharmaceutical composition characterized by a combination of bioactives selected from Glycine max seeds for its use in the modulation of the intestinal and cutaneous microbiota and the balance of the intestine-skin-brain axis.
WO2024104828A1 (en) Compositions
Code Proprietary human strain probiotic for extra daily support
FR3146578A1 (en) NEW ASSOCIATION BASED ON PROBIOTICS, COMPOSITIONS CONTAINING IT AND ITS USES
ES2957341A1 (en) HERICIUM ERINACEUS STRAIN AND ITS USE IN NEURODEGENERATIVE DISEASES, CANCER AND DIGESTIVE DISEASES (Machine-translation by Google Translate, not legally binding)
CN111317132A (en) Papaya enzyme composition for assisting in enhancing digestion and absorption functions of critically ill patients, preparation method and composite nano-preparation
WO2009116887A1 (en) Pharmaceutical composition of antibiotics and prebiotics for preventing and treating dysbiosis during antibacterial therapy

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20230317

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4